Carboplatin and teniposide concurrent with radiotherapy in patients with glioblastoma multiforme
| Autor: | Carla Carollo, Alberto Rigon, Mario Ermani, Alba A. Brandes, Mario V. Fiorentino, Sergio Turazzi, Giuseppe Altavilla, Paolo Zampieri, Franca Chierichetti |
|---|---|
| Rok vydání: | 1998 |
| Předmět: |
Adult
Male Oncology Cancer Research medicine.medical_specialty medicine.medical_treatment Phases of clinical research Antineoplastic Agents Nitrosourea Compounds Carboplatin Necrosis chemistry.chemical_compound Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Radiation Injuries Antineoplastic Agents Alkylating Survival rate Aged Proportional Hazards Models Teniposide Carmustine Chemotherapy Brain Neoplasms business.industry Cancer Radiotherapy Dosage Middle Aged medicine.disease Antineoplastic Agents Phytogenic Combined Modality Therapy Survival Analysis Thrombocytopenia Surgery Survival Rate Radiation therapy Treatment Outcome chemistry Multivariate Analysis Disease Progression Female Glioblastoma business medicine.drug |
| Zdroj: | Cancer. 82:355-361 |
| ISSN: | 1097-0142 0008-543X |
| DOI: | 10.1002/(sici)1097-0142(19980115)82:2<362::aid-cncr17>3.0.co;2-x |
| Popis: | BACKGROUND The outcome after treatment for glioblastoma remains poor. Therefore, the authors evaluated the long term efficacy and toxicity of treatment with radiotherapy and concurrent carboplatin plus teniposide followed by three cycles of carmustine in patients who underwent resection for glioblastoma. METHODS Fifty-six newly diagnosed patients with glioblastoma underwent radiotherapy (1.8-2 gray [Gy]/day, 5 days a week using limited fields up to 60 Gy), and concurrent chemotherapy with carboplatin (350 mg/m2) on Days 1, 22, and 43, and teniposide (50 mg/m2) on Days 1, 2, 3, 22, 23, 24, 43, 44, and 45. Four weeks after the end of radiotherapy, patients were given carmustine (200 mg/m2) every 8 weeks for 3 cycles. Treatment then was suspended, but if disease progression was found, treatment was resumed using different drugs. RESULTS All 56 patients were evaluated for time to progression (TTP) and median survival time (MST). The TTP was 7.5 months and the MST was 12.5 months. Toxicity manifested as thrombocytopenia and in most cases was acceptable. Four patients (7.1%) had radiation necrosis at 2, 2, 7, and 9 months, respectively, from the end of radiotherapy. CONCLUSIONS The results obtained in the current study with concurrent radiochemotherapy in patients with glioblastoma are comparable to the best results reported using radiotherapy alone followed by chemotherapy with nitrosoureas. Cancer 1998;82:355-61. © 1998 American Cancer Society. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text